Business Wire

CMC Networks® Selects Juniper Networks to Provide AI-Driven SD-WAN Solution to Support its Customers Internationally

Share

Juniper Networks, (NYSE: JNPR) a leader in secure, AI-driven networks, announced today that CMC Networks, a global service provider offering market-leading networking solutions, is the first Juniper partner to offer a managed AI-driven SD-WAN solution in Africa. A dynamic and self-optimizing network will deliver a superior experience to CMC’s customers, allowing them to easily modify their services, add new locations and spin up and down network speeds. Time-to-market is significantly reduced, enabling CMC to provision services faster.

By leveraging Juniper’s unique Session Smart® Router technology driven by Mist AI, CMC is delivering a unique tunnelless solution that is designed for scale and agility, coupled with automated provisioning, management and troubleshooting for maximum uptime, superior performance of real-time traffic and lower operating costs in both rural and urban environments.

News highlights:

  • CMC chose the Session Smart Router and standardized on Juniper’s STEP (Service and Topology Exchange Protocol) in order to navigate network traffic with real-time data information. This allows accurate and immediate decision making autonomously, minimizing delays to ensure that network traffic arrives at its destination in the most efficient way possible. This helps to ensure that CMC’s customers receive a SD-WAN service that is high-performing, secure and reliable.
  • The Juniper solution includes Secure Vector Routing (SVR), a transformational new intelligent routing architecture that enables CMC’s network to differentiate the way it delivers applications and services to end users. The SVR allows a network to identify problems and automatically decide the most effective path to re-route traffic. This supports business applications without user intervention, in support of the best possible user experience.
  • The Juniper® Session Smart Router (SSR) fuels an advanced, service-centric networking solution and Mist AI engine that takes software-defined routing and SD-WAN to a new level. The SSR enables agile, secure, and resilient WAN connectivity. With tunnelless SSR technology, each session is secured with zero trust access by default, providing the highest level of security. Additionally, eliminating tunnel overhead increases bandwidth capacity and enables an improved user experience.
  • CMC has been rolling out Session Smart Routers in Africa for the last three years, leveraging the organization’s scale and footprint to enable digital transformation across the region. In the future, the company plans to broaden its footprint into additional regions and deliver even more AI-driven managed services powered by Juniper, including wireless access.
  • CMC is in the process of planning the rollout of additional cloud-hosted services driven by Mist AI, including WAN Assurance and the Marvis™ Virtual Network Assistant. These further streamline the deployment, operations and troubleshooting of its AI-driven SD-WAN environment with zero touch provisioning, customizable service levels, self-driving operations and AI-driven support to proactively address problems before customers even know they exist.

Supporting Quotes:

“SD-WAN is not a new technology and every SD-WAN player gives customers speed and power on the network. However, digital transformation strategies require a high level of intelligence, support and the ability to underpin business-critical applications - attributes that many SD-WAN vendors can’t provide. Juniper’s AI-driven SD-WAN gives CMC a level of intelligence and operational insight that we haven’t seen before.”

Geoff Dornan, Chief Technology Officer, CMC Networks

"Juniper’s AI-driven SD-WAN solution, powered by our Session Smart Router and Mist AI, enables us to be laser-focused on optimizing user experience. We recognized early that networks must be application-aware to support the demands of the evolving enterprise and to deliver the highest levels of user experience. Juniper ticks all the necessary boxes by delivering on the promise of a truly intelligent network that adapts as user requirements change. Juniper is thrilled that our innovative work with CMC has yielded this much-needed solution to enable consistent and excellent user experiences, even in the most challenging geographies, and we look forward to continued collaboration."

Sue Graham Johnston, Vice President and General Manager, Juniper Networks

Additional Resources:

CMC Networks: Connecting African & Middle Eastern Communities with Secure, Reliable SD-WAN (video)

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Category-Service Provider

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blackstone and Hudson Pacific Properties Announce Plans for New World-Class Film and TV Studios in the UK2.8.2021 09:00:00 CEST | Press release

Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005278/en/ Artist Impression No. 1 (Photo: Business Wire) Funds managed by Blackstone Real Estate Partners and Hudson Pacific Properties acquired a 91-acre site, 17 miles north of central London, through a joint venture for £120 million. The acquisition, with an expected total investment of over £700 million, will be the partners’ first expansion of their Sunset Studios platform outside of the US. The proposed development, which is subject to planning permission, would transform the site into one of the largest world-class film and television studio campuses. The project is expected to create over 4,500 permanent jobs for Broxbourne and the surrounding community and contribute more than £300 million annually int

AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies2.8.2021 08:00:00 CEST | Press release

South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando. Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees. The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments. „I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, A

Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract2.8.2021 08:00:00 CEST | Press release

Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America. Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospi

Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders2.8.2021 07:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210801005028/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas.1 Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use.1,2 Exicure’s SNAs provide distinct chemical and biochemical properties to oligonucleotides. I

Arqit Releases QuantumCloud™ to Deliver Stronger, Simpler Encryption2.8.2021 06:20:00 CEST | Press release

Arqit Limited (“Arqit”), a leader in quantum encryption technology announces the release of the first version of its service, QuantumCloud™ 1.0. This Platform‑as‑a‑Service software enables customers to secure the communications channels and data of any cloud, edge or end-point device. The service combines transformational and unique advances in both quantum and classical cryptography. The release of QuantumCloud™ 1.0 allows customers to secure devices globally by providing a strong device authentication capability, over which is layered the agreement of symmetric keys between authenticated and authorised devices. Importantly, since there are no asymmetric cryptographic primitives used within the trustless key agreement protocol, the keys can be regarded as safe against future attack using Shor’s algorithm running on a quantum computer. A range of other features will be added in future quarters, culminating in the launch of Arqit’s proprietary quantum satellites, which is targeted for 2

Arqit Registration Statement Related to Business Combination With Centricus Acquisition Corp. Declared Effective By SEC2.8.2021 06:04:00 CEST | Press release

Arqit Limited (“Arqit”), a leader in quantum encryption technology today announced the Registration Statement on Form F-4 in connection with the previously announced business combination (the “Business Combination”) with Centricus Acquisition Corp. (“Centricus”) (Nasdaq: CENHU, CENH, CENHUW), a publicly-listed special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (the “SEC”). Upon closing, the ordinary shares and warrants of Arqit Quantum Inc., a company formed for purposes of completing the Business Combination, will be listed on NASDAQ under the new ticker symbols “ARQQ” and “ARQQW.” The boards of directors of Arqit and Centricus have unanimously approved the Business Combination, and Centricus has set 9:00 a.m. ET on August 31, 2021 as the time and date for an extraordinary general meeting of shareholders to approve the proposals associated with the Business Combination. The proxy statement/prospectus contains important informatio

Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie2.8.2021 01:30:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means including appealing the decision to the Irish courts. On November 28, 2018, Shire received a tax assessment from the Irish Revenue Commissioners for 398 million EUR. This assessment sought to tax a 1,635 million USD break fee Shire received from AbbVie in connection with the terminated offer to acquire Shire made by AbbVie in 2014. Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission. While Takeda is continuing to assess the substance of the decision, the company will record a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom